NC
AUPH icon

NinePointTwo Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

NinePointTwo Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$215K Hold
23,962
– – 0.09% 211
2023
Q3 		$186K Sell
23,962
-1,842
-7% -$18K 0.08% 223
2023
Q2 		$249K Buy
+25,804
New +$268K 0.1% 138
2023
Q1 		– Sell
-18,940
Closed -$81K – 264
2022
Q4 		$81K Hold
18,940
– – 0.03% 179
2022
Q3 		$142K Buy
+18,940
New +$164K 0.06% 165

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

NinePointTwo Capital's AUPH Position: Q4 2023 in Review

NinePointTwo Capital held its Aurinia Pharmaceuticals (AUPH) position steady in Q4 2023 at 23,962 shares worth $215K. The position accounts for 0.09% of the portfolio, ranked #211.

NinePointTwo Capital first reported a position in AUPH in Q3 2022 and has held it in 5 quarters since. The position peaked at $249K in Q2 2023. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

  • NinePointTwo Capital held 23,962 shares of Aurinia Pharmaceuticals worth $215K as of Q4 2023.
  • NinePointTwo Capital left its Aurinia Pharmaceuticals share count unchanged in Q4 2023.
  • Aurinia Pharmaceuticals made up 0.09% of NinePointTwo Capital's portfolio in Q4 2023, its #211 holding.
  • NinePointTwo Capital first reported a position in Aurinia Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
  • NinePointTwo Capital's Aurinia Pharmaceuticals position peaked at $249K in Q2 2023.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.